Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

					or Se	ction 30	(h) of the	Investr	nent Co	omp	any Act c	of 194	40						
1. Name and Address of Reporting Person* <u>Gheuens Sarah</u>					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC.									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
						AGIO]								X Officer below)	(give title		Other (s below)	pecify	
(Last) (First) (Middle) 88 SIDNEY STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/18/2022								Chief Medical Officer						
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
CAMBRI	DGE MA	Λ 0	2139										- 1	Y Form filed by One Reporting Person					
(City)	(Sta	ite) (7	ip)												Form filed by More than One Reporting Person				
(City)	(510	, ,																	
			e I - Nor					.	d, Di	÷		_			y Owned				
Date				Date	ransaction e onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		n D	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				5) Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following		: Direct I r Indirect E str. 4) (7. Nature of Indirect Beneficial Ownership (Instr. 4)
									le V	A	Amount		(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			
Common s	stock			02/18/	2022			M			3,271		A	\$0	\$0 8,723 D				
Common s	stock			02/22/	2022			F			955		D	\$29.0	\$29.08 7,768 D				
		Ta									sed of, nvertib				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	nversion Date Execution Date, Transaction Of Exercise (Month/Day/Year) (Month		erivative ecurities equired) or sposed (D) nstr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)					Security d 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
			- 1			l		l				Or	I	I	- 1		1		

Explanation of Responses:

- 1. Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

(D)

Date Exercisable

(2)

Expiration Date

(2)

Title

stock

Remarks:

Performance

share units

/s/ William Cook, as attorneyin-fact for Sarah Gheuens

of Shares

3,271

\$<mark>0</mark>

02/23/2022

3,272

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/18/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.